Accordingly, our network model showed that circKAT6A could control the platelet-derived growth factor (PDGF) signaling pathway, cholecystokinin (CCKR) signaling, and B-cell activation in CLL. The gene discussed is CCK; the disease is B-cell chronic lymphocytic leukemia.